Business Wire

Kape Technologies & ExpressVPN Announce Zac Eller as GM, Global Partnerships & Business Development

14.8.2024 15:00:00 EEST | Business Wire | Press release

Share

Kape Technologies and ExpressVPN today announce the appointment of Zac Eller as GM, Global Partnerships & Business Development, strengthening the group’s senior commercial team as they continue to expand their product offerings and services, building a safer, freer internet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240814518374/en/

Zac Eller (Photo: Business Wire)

The former Sony, Netflix, and Fox executive brings years of successfully scaling subscription-led growth businesses across the technology, media, and digital services sectors through strategic partnerships and new business channels.

In his new role, Eller will lead the group’s global partnerships and business development initiatives for Kape’s privacy products, including its flagship privacy brand, ExpressVPN. Eller will be focused on building new partnerships and B2B channels to drive growth and awareness for Kape’s best-in-category digital apps and services.

At Netflix, Eller contributed to the development of strategic partnerships that enhanced the platform’s global reach and content offerings. During his tenures at Sony and Fox, he spearheaded global partner initiatives, resulting in impactful collaborations that increased brand recognition, drove revenue, and expanded the subscriber base. Most recently, he managed the international digital services business at Travel + Leisure, where he was responsible for launching multi-platform travel products and content.

Ankit Khemka, Kape Technologies and ExpressVPN CMO, says “We are delighted to welcome Zac to the team during this new period of growth and innovation. His extensive experience and demonstrated success in scaling influential digital brands will be invaluable to us as we build a safer, freer digital world.”

“I’m excited to join Kape Technologies and ExpressVPN during this next stage of growth for the company,” says Zac Eller. “ExpressVPN is at the forefront of digital privacy and security innovation, and I look forward to working with the talented team to drive growth and deliver exceptional value to our partners and customers.”

About ExpressVPN

Since 2009, ExpressVPN has empowered millions of users to take control of their internet experience. The company’s award-winning consumer VPN service is backed by its open-source VPN protocol, Lightway, delivering user privacy in just a few clicks. ExpressVPN’s Keys password manager and Aircove router make digital privacy and security easy and accessible for all. ExpressVPN's products have been extensively vetted by third-party experts, including PwC, Cure53, KPMG and others.

ExpressVPN has been part of Kape Technologies since 2021. To learn more about ExpressVPN’s industry-leading privacy and security solutions, visit www.expressvpn.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240814518374/en/

Contacts

Media:
Max Borges Agency for ExpressVPN
expressvpn@maxborgesagency.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release

Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin

BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release

BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels

Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye